首页> Cancers> Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications.

Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications.

导出 OA

翻译打印收藏纠错

第一作者： Ewan,Hunter

第一单位： Oxford BioDynamics Plc., Oxford OX4 2WB, UK.

作者： Ewan,Hunter ^[1] ; Matthew,Salter ^[1] ; Ryan,Powell ^[1] ; Ann,Dring ^[1] ; Tarun,Naithani ^[1] ; Maria Eleni,Chatziioannou ^[1] ; Abel,Gebregzabhar ^[1] ; Mutaz,Issa ^[1] ; Jayne,Green ^[1] ; Serene,Ng ^[2] ; Chun Ren,Lim ^[2] ; Cheah Soon,Keat ^[3] ; Ang Tick,Suan ^[4] ; Rakesh,Raman ^[4] ; Ho Kean,Fatt ^[4] ; Fabian Lee Wei,Luen ^[4] ; Heba,Alshaker ^[5] ; Dmitri,Pchejetski ^[5] ; Dave,Blum ^[6] ; Thomas,Guiel ^[6] ; Robert,Heaton ^[6] ; Jedd,Levine ^[6] ; Alexandre,Akoulitchev ^[1]

作者单位： Oxford BioDynamics Plc., Oxford OX4 2WB, UK. ^[1] Oxford BioDynamics (M) Sdn Bhd, Penang 10470, Malaysia. ^[2] Mount Miriam Cancer Hospital (MMCH), Penang 11200, Malaysia.;Island Hospital, Penang 10450, Malaysia. ^[3] Mount Miriam Cancer Hospital (MMCH), Penang 11200, Malaysia. ^[4] School of Medicine, University of East Anglia, Norwich NR4 7TJ, UK. ^[5] Oxford BioDynamics Inc., Gaithersburg, MD 20878, USA. ^[6]

关键词 blood test epigenetics immune checkpoint inhibitors immuno-oncology response to treatment

DOI 10.3390/cancers15102696

PMID 37345033

发布时间 2023-07-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交